Summit Therapeutics Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-09-18

Reporting Person: Stefanov Ventzislav (Director, See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14900	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.37	2029-12-23	Common Stock (200000)		Direct
Stock Option (right to buy)	$3.30	2030-05-01	Common Stock (1000000)		Direct
Stock Option (right to buy)	$3.30	2030-05-01	Common Stock (27273)		Direct
Stock Option (right to buy)	$3.31	2030-07-08	Common Stock (200000)		Direct

Footnotes

F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Summit Therapeutics Inc., a Delaware corporation ("New Summit") to the attributes of Summit Therapeutics plc, a public limited company incorporated in England and Wales ("Old Summit"), the predecessor issuer. The succession occurred following the effectiveness, on September 18, 2020, of a United Kingdom court-approved scheme of arrangement in which every five ordinary shares, 0.01 pound sterling par value per share, of Old Summit were exchanged for one share of common stock, $0.01 par value per share, of New Summit, which resulted in New Summit becoming the holding company of Old Summit and its subsidiaries.

F2: The option was granted on December 23, 2019. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, or sooner on the happening of certain corporate events reflecting the achievement of the company's long-term objectives.

F3: The option was granted on May 1, 2020. The shares underlying the option are scheduled to vest quarterly over a four year period subject to the satisfaction of certain performance targets.

F4: The option was granted on May 1, 2020. The shares underlying the option are scheduled to vest in full on May 1, 2021.

F5: The option was granted on July 8, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date subject to the satisfaction of certain performance targets.